For employers, advisors, and individuals alike, 2026 won't just be about reacting to these changes — it will be about mastering a new landscape of high-cost innovation and shifting federal support.

Roughly 5.1% of U.S. adults may now be using GLP-1 agonists to try to control their weight, according to <a href="https://news.ehealthinsurance.com/" target="_blank" link-data="{&quot;cms.site.owner&quot;:{&quot;_ref&quot;:&quot;0000018e-8611-dbad-a9af-fe79f4ec0000&quot;,&quot;_type&quot;:&quot;ae3387cc-b875-31b7-b82d-63fd8d758c20&quot;},&quot;cms.content.publishDate&quot;:1764830989726,&quot;cms.content.publishUser&quot;:{&quot;_ref&quot;:&quot;00000192-f502-d200-a19b-fd17f90c0000&quot;,&quot;_type&quot;:&quot;6aa69ae1-35be-30dc-87e9-410da9e1cdcc&quot;},&quot;cms.content.updateDate&quot;:1764830989726,&quot;cms.content.updateUser&quot;:{&quot;_ref&quot;:&quot;00000192-f502-d200-a19b-fd17f90c0000&quot;,&quot;_type&quot;:&quot;6aa69ae1-35be-30dc-87e9-410da9e1cdcc&quot;},&quot;link&quot;:{&quot;attributes&quot;:[],&quot;target&quot;:&quot;NEW&quot;,&quot;url&quot;:&quot;https://news.ehealthinsurance.com/&quot;,&quot;_id&quot;:&quot;0000019a-e81f-d61b-a3be-ebdf96590000&quot;,&quot;_type&quot;:&quot;33ac701a-72c1-316a-a3a5-13918cf384df&quot;},&quot;theme.bundle-default.:link:LinkEnhancement.hbs._template&quot;:null,&quot;theme.bundle-default.:link:LinkEnhancement.hbs._preset&quot;:null,&quot;_id&quot;:&quot;0000019a-e81f-d61b-a3be-ebdf96590001&quot;,&quot;_type&quot;:&quot;02ec1f82-5e56-3b8c-af6e-6fc7c8772266&quot;}">eHealth</a>.

The American Hospital Association and Maine Hospital Association on Monday filed a lawsuit in U.S. District Court in Maine to stop upcoming changes to the federal 340B Drug Pricing Program.

The drugmakers will offer Zepbound and Wegovy to companies starting Jan. 1 through Waltz Health, a firm that helps employers purchase cheaper medications.